Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang în acțiuni
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Preț acțiune
$4.48
Capitalizare de piață
$4.99B
Schimbare (1 zi)
-5.20%
Schimbare (1 an)
-41.89%
Țară
CN
Tranzacționează Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categorie
Healthcare
Câștiguri pentru Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Câștiguri în Jun 2026 TTM: $95.41M
Conform celor mai recente rapoarte financiare ale Shenzhen Salubris Pharmaceuticals Co., Ltd., câștigurile actuale ale companiei sunt $95.41M. În anul 2024, compania a înregistrat un câștig de $86.66M, o scădere comparativ cu câștigului din 2023, care a fost de $90.66M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Shenzhen Salubris Pharmaceuticals Co., Ltd. din 2006 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $95.41M | 1.77% |
| 2025 | $93.75M | 8.18% |
| 2024 | $86.66M | -4.42% |
| 2023 | $90.66M | -12.38% |
| 2022 | $103.47M | 9.64% |
| 2021 | $94.38M | 986.53% |
| 2020 | $8.69M | -92.90% |
| 2019 | $122.26M | -50.71% |
| 2018 | $248.05M | -5.91% |
| 2017 | $263.64M | 10.90% |
| 2016 | $237.72M | 3.50% |
| 2015 | $229.68M | 16.86% |
| 2014 | $196.54M | 22.09% |
| 2013 | $160.97M | 33.79% |
| 2012 | $120.32M | 59.83% |
| 2011 | $75.28M | 19.59% |
| 2010 | $62.95M | 72.35% |
| 2009 | $36.52M | 96.81% |
| 2008 | $18.56M | 76.92% |
| 2007 | $10.49M | 123.31% |
| 2006 | $4.70M | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $3.62B | 3,693.17% |
US
|
|
| $4.11B | 4,206.59% |
FR
|
|
| $2.19B | 2,197.71% |
JP
|
|
| $1.59B | 1,566.52% |
US
|
|
| - | - |
CH
|
